Interpace Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $158.0K | $721.0K | $22.7M | $911.0K | $-640.0K | $1.6M | $1.9M | $1.7M |
| Depreciation & Amortization | $127.0K | $118.0K | $118.0K | $111.0K | $101.0K | $95.0K | $96.0K | $85.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.0K | $4.0K | $4.0K | $7.0K | $9.0K | $15.0K | $73.0K | $86.0K |
| Net Cash from Operating Activities | $98.0K | $283.0K | $2.1M | $1.9M | $520.0K | $1.2M | $1.2M | $2.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $57.0K | $141.0K | — | — | — | — | $129.0K | $522.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-57.0K | $-141.0K | — | — | — | — | $-129.0K | $-522.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | $-1.0M | $-900.0K | $-1.0M | $-1.5M | $-1.7M | $-1.5M |
| Net Change in Cash | $41.0K | $142.0K | $1.1M | $921.0K | $-694.0K | $-265.0K | $-652.0K | $94.0K |
| Free Cash Flow | $41.0K | $142.0K | — | — | — | — | $1.1M | $1.6M |